LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience in vaccine development with considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments.

法国里昂——（商业新闻短讯）——Osivax是一家开发疫苗以提供针对高度突变的传染性病毒和疾病的广谱保护的生物制药公司，今天宣布任命NicolaGroth博士为执行委员会首席医疗官。她拥有超过25年的疫苗开发经验，在流感疫苗方面拥有丰富的专业知识，从早期临床开发到批准和上市后承诺。

Dr. Groth joins Osivax as the company advances the development of its lead candidate, OVX836, a best-in-class broad-spectrum influenza vaccine candidate currently being evaluated in several Phase 2 clinical trials. Dr. Groth takes over from Dr. Willems, whose contribution has been instrumental in advancing Osivax’ clinical strategy..

Groth博士加入了Osivax，该公司正在推进其主要候选疫苗OVX836的开发，OVX836是目前正在进行多项2期临床试验评估的同类最佳广谱流感疫苗候选疫苗。Groth博士接替Willems博士，Willems博士的贡献有助于推进Osivax的临床策略。。

“We are thrilled to announce the addition of Nicola to our executive team as CMO. With her extensive leadership background in vaccine development and interactions with regulatory agencies, particularly in influenza vaccines, she brings invaluable expertise to our organization. Nicola’s experience in managing late-stage clinical trials and building registration packages for influenza vaccines will be crucial as we progress OVX836 through Phase 2 clinical testing and approach the clinic with our universal coronavirus vaccine candidate, OVX033,” commented Alexandre Le Vert, CEO and Co-Founder of Osivax.

“我们很高兴宣布尼古拉加入我们的执行团队担任首席营销官。凭借她在疫苗开发以及与监管机构（尤其是流感疫苗）的互动方面的广泛领导背景，她为我们的组织带来了宝贵的专业知识。尼古拉在管理晚期临床试验和建立流感疫苗注册包方面的经验Osivax首席执行官兼联合创始人亚历山大·勒维特（Alexandre Le Vert）评论道：“随着我们通过OVX836进行第二阶段临床测试并使用我们的通用冠状病毒候选疫苗OVX033进入临床，这将至关重要。”。

“I would also like to express my gratitude for the contributions of Dr. Paul Willems, MD, whose dedication has brought Osivax to this point of development.”.

“我还要感谢医学博士Paul Willems博士的贡献，他的奉献精神将Osivax带到了这一发展点。”。

“Joining the high-performing team at Osivax represents a unique opportunity to support the development of a new class of vaccines capable of providing broad-spectrum protection against infectious viruses and diseases that continue posing global health threats,” said Dr. Nicola Groth, CMO of Osivax. “I am eager to lend my expertise to further drive Osivax’ clinical programs and impact in this field.”.

Osivax首席营销官尼古拉·格罗斯（NicolaGroth）博士说：“加入Osivax的高绩效团队是一个独特的机会，可以支持开发一类新型疫苗，能够提供广谱保护，抵御继续构成全球健康威胁的传染性病毒和疾病。”。“我渴望将我的专业知识用于进一步推动Osivax在该领域的临床计划和影响。”。

Before joining Osivax, Dr. Groth served as Global Head of Safety Evaluation & Risk Management at GlaxoSmithKline (GSK) Vaccines. She has also held various strategic positions in vaccine development, epidemiology, and medical affairs at Novartis Vaccines and Diagnostics and the Chiron Corporation. Nicola Groth holds a Doctor of Medicine and a PhD in Hygiene and Preventive Medicine from the University of Siena, Italy..

在加入Osivax之前，Groth博士曾担任葛兰素史克（GlaxoSmithKline）疫苗安全评估和风险管理全球负责人。她还在诺华疫苗与诊断公司和凯龙公司担任疫苗开发、流行病学和医疗事务方面的各种战略职位。Nicola Groth拥有意大利锡耶纳大学的医学博士和卫生与预防医学博士学位。。

About Osivax

关于Osivax

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 subjects tested and encouraging efficacy proof of concept data.

Osivax是一家临床阶段的生物制药公司，利用其新颖的自组装纳米粒子平台技术oligoDOM®，开发出具有转化性的一流泛呼吸道病毒疫苗，除了产生强大而持续的B细胞反应外，还产生优异的T细胞反应。该公司正在通过其广谱“通用”流感候选物OVX836建立概念验证，该候选物目前正在进行2期临床试验，测试了1200多名受试者，并鼓励了概念验证数据的有效性。

Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide..

Osivax的目标是开发一种泛呼吸道病毒疫苗，以一次性预防所有流感病毒株和所有沙伯病毒变异。该公司将通过在全球范围内的组合和合作，扩展到其他传染病适应症。。

For further information: https://osivax.com/

更多信息：https://osivax.com/